LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Lista de Ações・Heron Therapeutics Inc

Heron Therapeutics Inc

Abrir

SetorSaúde

0.45 7.14

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.42

Máximo

0.47

Indicadores-chave
By Trading Economics
Rendimento	-5.2M -8.1M
Vendas	-5.9M 35M
EPS	-0.04
Margem de lucro	-23.367
Funcionários	128
EBITDA	-4M -4.8M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+365.12% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-74M 157M
Abertura anterior	-6.69
Fecho anterior	0.45

Sentimento de Notícias

By Acuity

70%

30%

292 / 344 Ranking em Healthcare

Heron Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2026, 19:20 UTC

Grandes Movimentos do Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 de jun. de 2026, 23:36 UTC

Conversa de Mercado

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 de jun. de 2026, 18:00 UTC

Ganhos

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 de jun. de 2026, 12:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Correction to Texas Billionaires Article America's Resort -- WSJ

6 de jun. de 2026, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

6 de jun. de 2026, 08:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

6 de jun. de 2026, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de jun. de 2026, 00:14 UTC

Aquisições, Fusões, Aquisições de Empresas

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 de jun. de 2026, 21:27 UTC

Ganhos

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 20:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 de jun. de 2026, 20:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 de jun. de 2026, 19:10 UTC

Conversa de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 de jun. de 2026, 19:03 UTC

Conversa de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 de jun. de 2026, 18:59 UTC

Conversa de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 de jun. de 2026, 18:47 UTC

Conversa de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 de jun. de 2026, 18:34 UTC

Conversa de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 de jun. de 2026, 18:33 UTC

Aquisições, Fusões, Aquisições de Empresas

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 de jun. de 2026, 17:50 UTC

Ganhos

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 de jun. de 2026, 17:27 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 de jun. de 2026, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

5 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Heron Therapeutics Inc Previsão

Preço-alvo

By TipRanks

365.12% parte superior

Previsão para 12 meses

Média 2 USD 365.12%

Máximo 2 USD

Mínimo 2 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

292 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.